Plant Name: Salvia lasiantha
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 7.907E-12 | 8.608E-08 | CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 1.047E-10 | 5.701E-07 | CYP2A13, CYP2A6, CYP2C19, CYP2D6, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 2.600E-10 | 9.436E-07 | CYP1A2, CYP2A6, CYP2C19, CYP3A4 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 4.570E-10 | 1.422E-06 | CYP1A2, CYP2A13, CYP2C19, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 7.157E-10 | 1.948E-06 | CA12, CA13, CA7, CA9 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.309E-09 | 2.850E-06 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 3.127E-09 | 5.675E-06 | CYP1A2, CYP2A13, CYP2A6, CYP2C19 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 4.622E-09 | 6.868E-06 | CYP1A2, CYP2A13, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 5.027E-09 | 6.868E-06 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009804; coumarin metabolic process | 2.373E-08 | 2.272E-05 | CYP2A13, CYP2A6, CYP2D6 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 3.051E-08 | 2.658E-05 | CA12, CA13, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 5.282E-08 | 3.834E-05 | CYP1A2, CYP2A13, CYP2C19, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 6.716E-08 | 4.718E-05 | CYP1A2, CYP2A6, CYP2C19, CYP2D6, CYP3A4, NPC1 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 6.999E-08 | 4.763E-05 | CA12, CA13, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.487E-07 | 9.251E-05 | CYP1A2, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 4.583E-07 | 2.495E-04 | CYP2A13, CYP2A6, CYP2C19 |
| MF | GO:0003824; catalytic activity | GO:0008389; coumarin 7-hydroxylase activity | 8.202E-07 | 4.252E-04 | CYP2A13, CYP2A6 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 2.459E-06 | 1.245E-03 | CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 4.916E-06 | 2.327E-03 | CYP1A2, CYP3A4 |
| CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 1.097E-05 | 4.778E-03 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2D6, CYP3A4, RAB9A |
| BP | GO:0050896; response to stimulus | GO:0046686; response to cadmium ion | 1.826E-05 | 7.364E-03 | CYP1A2, MAPK1, NPC1 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 3.489E-09 | 1.644E-07 | CYP2A6; CYP2D6; CYP1A2; CYP3A4; CYP2C19 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 4.654E-09 | 1.644E-07 | CYP2A6; CYP2A13; CYP2D6; CYP1A2; CYP3A4 |
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.085E-09 | 1.150E-07 | CA12; CA7; CA9; CA13 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 8.412E-09 | 2.229E-07 | CYP2A6; CYP2A13; CYP1A2; CYP3A4; CYP2C19 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 3.004E-07 | 6.369E-06 | CYP2A6; CYP1A2; ALDH1A1; CYP3A4 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 2.204E-06 | 3.894E-05 | CYP1A2; CYP3A4; CYP2C19 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 3.969E-05 | 5.259E-04 | CASP7; CASP1; MAPK1 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.312E-04 | 1.545E-03 | CYP2D6; MAPK1; CYP2C19 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 5.430E-04 | 5.233E-03 | CYP2A6; CYP1A2; ALDH1A1; CYP2C19; CYP3A4; HSD17B10 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 4.330E-04 | 4.590E-03 | CASP7; MAPK1; HSD17B10 |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 1.104E-03 | 8.674E-03 | CASP7; CASP1 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 7.735E-04 | 6.832E-03 | CYP2A6; CYP3A4 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 1.186E-03 | 8.674E-03 | CASP1; MAPK1 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.227E-03 | 8.674E-03 | CYP1A2; CYP3A4 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 4.330E-03 | 2.700E-02 | CASP7; MAPK1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 6.916E-03 | 4.073E-02 | CASP7; MAPK1 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 2.674E-03 | 1.771E-02 | CASP1; MAPK1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 7.638E-06 | 1.157E-04 | CYP2A6; CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CASP1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MAPK1; CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6 |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9 |
| C00-D49: Neoplasms | Cancer | C00-C96 | MAPK1; CA9 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | CASP1 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | CASP1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |